Klaus G Parhofer

List of Publications by Year
in descending order

67 papers	11,038 citations	61984 43 h-index	102487 66 g-index
70 all docs	70 docs citations	70 times ranked	11407 citing authors

#	Article	IF	Citations
1	New targets for treating hypertriglyceridemia. Current Opinion in Endocrinology, Diabetes and Obesity, 2022, Publish Ahead of Print, .	2.3	1
2	Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid. , 2022, 237, 108172.		18
3	Effect of PCSK9 inhibition with evolocumab on lipoprotein subfractions in familial dysbetalipoproteinemia (type III hyperlipidemia). PLoS ONE, 2022, 17, e0265838.	2.5	8
4	Hypercholesterolemia Diagnosis, Treatment Patterns, and 12-Month Target Achievement in Clinical Practice in Germany in Patients with Familial Hypercholesterolemia. Journal of Clinical Medicine, 2022, 11, 3810.	2.4	2
5	Postprandial Lipid Metabolism in Normolipidemic Subjects and Patients with Mild to Moderate Hypertriglyceridemia: Effects of Test Meals Containing Saturated Fatty Acids, Mono-Unsaturated Fatty Acids, or Medium-Chain Fatty Acids. Nutrients, 2021, 13, 1737.	4.1	10
6	Oral Lipid-Lowering Treatments Beyond Statins: Too Old and Outdated or Still Useful?. Current Atherosclerosis Reports, 2021, 23, 74.	4.8	0
7	Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement. Lancet Diabetes and Endocrinology,the, 2020, 8, 50-67.	11.4	114
8	Clinical review on triglycerides. European Heart Journal, 2020, 41, 99-109c.	2.2	286
9	Efficacy and safety of icosapent ethyl in hypertriglyceridaemia: a recap. European Heart Journal Supplements, 2020, 22, J21-J33.	0.1	7
10	Evaluation of the effect of sodiumâ€“glucose coâ€transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPERORâ€Reduced trial. European Journal of Heart Failure, 2019, 21, 1270-1278.	7.1	155
11	Evaluation of the effects of sodiumâ€“glucose coâ€transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPERORâ€Preserved Trial. European Journal of Heart Failure, 2019, 21, 1279-1287.	7.1	205
12	The Diagnosis and Treatment of Hypertriglyceridemia. Deutsches Ärzteblatt International, 2019, 116, 825-832.	0.9	50
13	Predictors of Quality of Life and Other Patient-Reported Outcomes in the PANORAMA Multinational Study of People With Type 2 Diabetes. Diabetes Care, 2018, 41, 267-276.	8.6	81
14	Effects of a cluster-randomized school-based prevention program on physical activity and microvascular function (JuvenTUM 3). Atherosclerosis, 2018, 278, 73-81.	0.8	16
15	Diagnostic algorithm for familial chylomicronemia syndrome. Atherosclerosis Supplements, 2017, 23, 1-7.	1.2	94
16	Relationship of hyperlipidemia to comorbidities and lung function in COPD: Results of the COSYCONET cohort. PLoS ONE, 2017, 12, e0177501.	2.5	37
17	Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial. European Heart Journal, 2016, 37, 3588-3595.	2.2	174
18	Extended-Release Niacin/Laropiprant Improves Overall Efficacy of Postprandial Reverse Cholesterol Transport. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 285-294.	2.4	17

#	Article	IF	Citations
19	Lipoprotein apheresis to treat elevated lipoprotein (a). Journal of Lipid Research, 2016, 57, 1751-1757.	4.2	78
20	Whole-Body MR Imaging Including Angiography: Predicting Recurrent Events in Diabetics. European Radiology, 2016, 26, 1420-1430.	4.5	9
21	The Treatment of Disorders of Lipid Metabolism. Deutsches Ärzteblatt International, 2016, 113, 261-8.	0.9	55
22	Interaction between Glucose and Lipid Metabolism: More than Diabetic Dyslipidemia. Diabetes and Metabolism Journal, 2015, 39, 353.	4.7	272
23	Increasing HDL-cholesterol and prevention of atherosclerosis: A critical perspective. Atherosclerosis Supplements, 2015, 18, 109-111.	1.2	37
24	Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. European Journal of Preventive Cardiology, 2015, 22, 849-854.	1.8	60
25	The Diabetes Risk Phenotype of Young Women With Recent Gestational Diabetes. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E910-E918.	3.6	44
26	Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. European Heart Journal, 2015, 36, 2425-2437.	2.2	644
27	Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. European Heart Journal, 2014, 35, 2146-2157.	2.2	835
28	Current level of glycaemic control and its associated factors in patients with type 2 diabetes across Europe: data from the PANORAMA study. Clinical Endocrinology, 2014, 80, 47-56.	2.4	168
29	Integrated guidance on the care of familial hypercholesterolemia from the International FH Foundation. Journal of Clinical Lipidology, 2014, 8, 148-172.	1.5	98
30	Does Regular Lipid Apheresis in Patients With Isolated Elevated Lipoprotein(a) Levels Reduce the Incidence of Cardiovascular Events?. Artificial Organs, 2014, 38, 135-141.	1.9	70
31	Diabetic dyslipidemia. Metabolism: Clinical and Experimental, 2014, 63, 1469-1479.	3.4	344
32	Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. International Journal of Cardiology, 2014, 171, 309-325.	1.7	316
33	The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes and Endocrinology,the, 2014, 2, 655-666.	11.4	473
34	Walnut-enriched diet reduces fasting non-HDL-cholesterol and apolipoprotein B in healthy Caucasian subjects: A randomized controlled cross-over clinical trial. Metabolism: Clinical and Experimental, 2014, 63, 382-391.	3.4	75
35	Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. European Heart Journal, 2013, 34, 3478-3490.	2.2	2,132
36	Mipomersen: evidence-based review of its potential in the treatment of homozygous and severe heterozygous familial hypercholesterolemia. Core Evidence, 2012, 7, 29.	4.7	32

#	Article	IF	Citations
37	PANORAMA: A European study to evaluate quality of life and treatment satisfaction in patients with type-2 diabetes mellitusâ€"Study design. Primary Care Diabetes, 2011, 5, 231-239.	1.8	39
38	High-Dose Treatment With Telmisartan Induces Monocytic Peroxisome Proliferator-Activated Receptor-Î³ Target Genes in Patients With the Metabolic Syndrome. Hypertension, 2011, 58, 725-732.	2.7	31
39	Severe hypercholesterolaemia: therapeutic goals and eligibility criteria for LDL apheresis in Europe. Current Opinion in Lipidology, 2010, 21, 492-498.	2.7	95
40	Cardiovascular Event Rates in Diabetic and Nondiabetic Individuals With and Without Established Atherothrombosis (from the REduction of Atherothrombosis for Continued Health [REACH] Registry). American Journal of Cardiology, 2010, 105, 667-671.	1.6	60
41	Expression of Human Chemerin Induces Insulin Resistance in the Skeletal Muscle but Does Not Affect Weight, Lipid Levels, and Atherosclerosis in LDL Receptor Knockout Mice on High-Fat Diet. Diabetes, 2010, 59, 2898-2903.	0.6	89
42	Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia. Vascular Health and Risk Management, 2009, 5, 901.	2.3	20
43	Low Adiponectin Levels Are an Independent Predictor of Mixed and Non-Calcified Coronary Atherosclerotic Plaques. PLoS ONE, 2009, 4, e4733.	2.5	55
44	Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis. European Journal of Endocrinology, 2009, 161, 339-344.	3.7	257
45	Pericardial Adipose Tissue Determined by Dual Source CT Is a Risk Factor for Coronary Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 781-786.	2.4	243
46	Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nature Reviews Cardiology, 2009, 6, 229-239.	13.7	206
47	Systemic Cardiovascular Complications in Patients With Long-Standing Diabetes Mellitus. Investigative Radiology, 2009, 44, 242-250.	6.2	44
48	Adipokines and Insulin Resistance. Molecular Medicine, 2008, 14, 741-751.	4.4	673
49	CXCL16 is a surrogate marker of inflammatory bowel disease. Scandinavian Journal of Gastroenterology, 2008, 43, 283-288.	1.5	26
50	Resistin is an inflammatory marker of inflammatory bowel disease in humans. European Journal of Gastroenterology and Hepatology, 2007, 19, 1070-1074.	1.6	128
51	Effect of ezetimibe on low-density lipoprotein subtype distribution: results of a placebo-controlled, double-blind trial in patients treated by regular low-density lipoprotein apheresis and statins. Metabolism: Clinical and Experimental, 2006, 55, 599-604.	3.4	29
52	The effect of telmisartan on glucose and lipid metabolism in nondiabetic, insulin-resistant subjects. Metabolism: Clinical and Experimental, 2006, 55, 1149-1154.	3.4	81
53	Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). European Heart Journal, 2006, 28, 88-136.	2.2	1,144
54	Plasma separation and anion adsorption transiently relieve intractable pruritus in primary biliary cirrhosis. Journal of Hepatology, 2006, 45, 887-891.	3.7	48

#	Article	IF	Citations
55	PROGNOSTIC VALUE OF INTERLEUKIN 6, PROCALCITONIN, AND C-REACTIVE PROTEIN LEVELS IN INTENSIVE CARE UNIT PATIENTS DURING FIRST INCREASE OF FEVER. Shock, 2006, 26, 10-12.	2.1	90
56	Thematic review series: Patient-Oriented Research. What we have learned about VLDL and LDL metabolism from human kinetics studies. Journal of Lipid Research, 2006, 47, 1620-1630.	4.2	47
57	Long-term reduction of C-reactive protein concentration by regular LDL apheresis. Atherosclerosis, 2004, 174, 151-156.	0.8	42
58	Atorvastatin improves diabetic dyslipidemia and increases lipoprotein lipase activity in vivo. Atherosclerosis, 2004, 175, 325-331.	0.8	44
59	Comparison of current guidelines for primary prevention of coronary heart disease. Journal of General Internal Medicine, 2003, 18, 190-195.	2.6	30
60	Efficacy and Safety of a New Whole-blood Low-density Lipoprotein Apheresis System (Liposorber D) in Severe Hypercholesterolemia. Artificial Organs, 2003, 27, 1116-1122.	1.9	53
61	Effect of atorvastatin on postprandial lipoprotein metabolism in hypertriglyceridemic patients. Journal of Lipid Research, 2003, 44, 1192-1198.	4.2	45
62	Bowel Habits and Bile Acid Malabsorption in The Months After Cholecystectomy. American Journal of Gastroenterology, 2002, 97, 1732-1735.	0.4	78
63	Effect of atorvastatin on low-density lipoprotein subtypes in patients with different forms of hyperlipoproteinemia and control subjects. Metabolism: Clinical and Experimental, 2001, 50, 983-988.	3.4	40
64	Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia. American Journal of Cardiology, 2001, 87, 44-48.	1.6	111
65	Atorvastatin Improves Postprandial Lipoprotein Metabolism in Normolipidemic Subjects1. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 4224-4230.	3.6	54
66	The Prevention Education Program (PEP). A Prospective Study of the Efficacy of Family-Oriented Life Style Modification in the Reduction of Cardiovascular Risk and Disease. Journal of Clinical Epidemiology, 1999, 52, 791-800.	5.0	53
67	Apoprotein B-100 Production Is Decreased in Subjects Heterozygous for Truncations of Apoprotein B. Arteriosclerosis, Thrombosis, and Vascular Biology, 1995, 15, 71-80.	2.4	65